Osiris/Genzyme Put Stem Cells On The Deal Map
This article was originally published in The Pink Sheet Daily
Executive Summary
First-in-class MSC-based therapy Prochymal headed to regulators in 2009 for GvHD.
You may also be interested in...
Osiris Will Focus On Liver GvHD While Sorting Data From Failed Studies
"The idea of giving up and going home is simply not in the cards," CEO Mills says.
Osiris Will Focus On Liver GvHD While Sorting Data From Failed Studies
"The idea of giving up and going home is simply not in the cards," CEO Mills says.
Osiris Hiccup In COPD Barely Registers In Maturing Stem Cell Sector
The rapidly evolving stem cell space may have matured to the level where a single company’s misstep no longer raises questions about the viability of the whole endeavor. At least that seems to be the reaction following Osiris Therapeutics’ recent announcement that its mesenchymal stem cell therapy Prochymal produced mixed results in an interim look at a study of 62 patients with chronic obstructive pulmonary disease.